CAMBRIDGE, Mass., July 14,
2024 /PRNewswire/ -- Nona Biosciences, a global
biotechnology company providing a total solution from "Idea to IND"
(I to ITM), ranging from target validation and antibody
discovery through preclinical research, announced today that it has
entered into a collaboration agreement with Alaya.bio, a
biotechnology company developing a novel polymeric delivery
platform, to precisely target and reprogram cells in situ
and thus to significantly simplify the way CAR-T cell therapies in
particular are being developed, manufactured and administered.
This collaboration aims to leverage Nona's proprietary HCAb
Harbour Mice® platform and its newly introduced
site-specific conjugation technology, alongside Alaya.bio's
polymeric in situ delivery platform, to develop CAR-T
product candidates for potential clinical applications. Nona's
fully human HCAbs are revolutionizing antibody discovery with their
compact size, simplified structure, and precisely calibrated
binding properties, making them ideal for next-generation
biotherapeutics. Unlike traditional methods that utilize
non-specific conjugation technology, Nona's novel site-specific
conjugation technology preserves the antibody's binding and
function, thereby enhancing the specificity of Alaya.bio's novel
polymeric delivery systems while reinforcing the versatility of the
platform.
Under the first phase of the collaboration, Nona will provide
Alaya.bio with access to antibodies against multiple targets as
potential targeting moieties for Alaya.bio's in vivo CAR
program. In the second phase of the collaboration, Alaya.bio will
nominate one or more binders that will be conjugated onto their
polymeric nanoparticles in a site-specific manner using Nona's
site-specific conjugation technology to advance Alaya.bio's CAR
product candidate towards clinics.
Dr. Jingsong Wang, Chairman of
Nona Biosciences, stated, "We are excited to collaborate with
Alaya.bio in advancing CAR-T cell therapy. By combining Nona's
industry-leading technology and expertise with Alaya.bio's
innovative in situ polymeric delivery platform, we look
forward to introducing more promising CAR-T therapies to patients
worldwide."
Renaud Vaillant, CEO &
Co-founder of Alaya.bio, stated, "We are delighted to start this
collaboration between Alaya.bio and Nona Biosciences. The quality
of the targeting agents that we graft onto our polymeric
nanoparticle ensures the efficacy and safety of our technology.
With Nona Biosciences, we have identified promising new-generation
candidates that clearly differentiate from what exists and from
what has been used by others."
About Nona Biosciences
Nona Biosciences is a global biotechnology company committed to
cutting-edge technology innovations and providing a total solution
from "Idea to IND" ("I to ITM"), ranging from target
validation and antibody discovery through preclinical research. The
integrated antibody and antibody-related discovery services with
multiple modalities range from antigen preparation, animal
immunization, single B cell screening, to antibody lead generation
and engineering, developability assessment and pharmacological
evaluation, leveraging advantages of Harbour Mice®
platforms and the experienced therapeutic antibody discovery
team.
Harbour Mice® generate fully-human, monoclonal
antibodies in classical two light and two heavy chain (H2L2) and
heavy chain-only (HCAb) formats. Integrating Harbour
Mice® and a single B cell cloning platform, Nona
Biosciences is focused on driving global inventions of
transformative next-generation drugs. For more information, please
visit: www.nonabio.com.
About Alaya.bio
Alaya.bio is a pioneering biotechnology company dedicated to
advancing in situ gene delivery platform, particularly in
the field of CAR-T cell immunotherapy. Alaya.bio's proprietary
polymeric delivery nanoparticle offers precise targeting of cells
and organs, and enhanced delivery of a wide range of therapeutic
payloads, from viral vectors to nucleic acids (incl. mRNA). It can
be used either ex vivo (as part of rapid manufacturing
processes) or in situ (in situ transduction within
the patient after systemic administration). To learn more, please
visit: https://www.alaya.bio
View original
content:https://www.prnewswire.com/news-releases/nona-biosciences-enters-into-collaboration-agreement-with-alayabio-to-advance-car-t-cell-therapy-302196499.html
SOURCE Nona Biosciences